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Abstract
Objective: Invasive pulmonary aspergillosis is frequent in neutropenic patients. Usually localized in the beginning, the disease spreads
and mortality is high despite antifungal treatment. The role of early adjuvant surgery is not clear. Surgery may help to confirm fungal disease,
may control fungal disease locally and may prevent systemic spreading. This study examines effects of early resection on survival and
dissemination in a rat model of localized invasive pulmonary aspergillosis. Methods: Forty persistently neutropenic male albino rats were
challenged with standardized conidial aspergillus inoculum injected into peripheral lung tissue of the right upper lobe under direct vision.
Animals were divided into four groups. Twenty animals were treated with amphotericin B at 1 mg/kg per day beginning 48 h after
inoculation, 20 animals were left untreated. In each group half the animals underwent early resection of localized invasive aspergillosis
by lobectomy. Animals were checked daily and mortality was recorded up to 28 days after which surviving animals were sacrificed. Results:
Significantly higher survival was observed in resected animals in the non-Am B groups (survival: 10 ^ 19% without early resection and
50 ^ 32% with early resection; P ¼ 0:044). However, early resection did not lead to improved survival in animals treated with amphotericin
B (survival 70 ^ 29% without early resection and 50 ^ 32% with early resection; P ¼ 0:316). Conclusions: In this rat model of localized
invasive pulmonary aspergillosis effects of early resection on survival could be demonstrated only in animals not receiving amphotericin B
treatment. q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mortality of invasive pulmonary aspergillosis (IPA) is
reported to be 40–60% despite adequate medical treatment
[1]. Descriptive studies [2–9] and a recent retrospective
comparative cohort study [10] of surgically versus medi-
cally treated patients have reported lower case fatality
rates of 30% or less in surgically treated patients. Although
these results are promising, the role of early surgery in the
treatment of IPA in neutropenic hematological patients has
not been generally established given the lack of prospective
randomized studies.
In the present study a rat model of resection of localized
IPA is presented. The aim of this study is to follow an
established model of diffuse IPA in persistently neutropenic
rats initially developed for comparisons of antifungal drugs
[11,12] and to modify the model to observe the effects of
early resection of localized IPA on mortality and disease
dissemination.
2. Materials and methods
2.1. Animals
Forty male albino rats (Sprague–Dawley, specified patho-
gen free, weight 180–250 g; RCC Ltd., Fullinsdorf, Switzer-
land). The animals received humane care in compliance
with the European Convention on Animal Care and the
study was approved by the local institutional ethics commit-
tee (Supervisory Board for Animal Experiments, Kanto-
nales Veterinaeramt Basel; protocol #1772).
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2.2. Materials
Amphotericin B (Fungizone, Bristol-Myers Squibb);
cyclophosphamide (Endoxan, Asta Medica); amoxicillin
(Clamoxyl, SmithKline Beecham); gentamicin (Garamycin,
Essex Chemie); isoflurane (Forene, Abott), Sabouraud agar
(Biomerieux, Marcy l’Etoile, France for production of coni-
dia and Becton Dickinson, Meylan Cedex, France for
controls).
2.3. Anesthesia
All intraperitoneal (i.p.) and intramuscular (i.m.) injec-
tions and all surgical procedures were performed under
spontaneous ventilation with an isoflurane/oxygen gas
mixture (evaporation system: Medical Supplies & Services
Int. Ltd., UK) in an induction box and/or on an operation
table with a mask and waste-air suction system (Vet-Anest
System, Provet Ltd., Lyssach, Switzerland).
2.4. Fungal strain
A strain of Aspergillus fumigatus was isolated from a fatal
case of leukemia with disseminated IPA. MIC of amphoter-
icin B for this strain was 0.5 mg/l. The fungus was cultured
at 37 8C on Sabouraud agar and conidia were harvested in
sterile saline. Preparation of a microscopically confirmed
hyphal-free conidial suspension was performed as described
by Leenders et al. [11]. A suspension of 5 £ 105 conidia/ml
was produced freshly a few hours before inoculation. Each
inoculum consisted of 0.02 ml of suspension (1 £ 104 coni-
dia) in separate syringes (Micro Fine 0.5 ml, Becton Dick-
inson, Meylan Cedex, France). Viability of conidia in
inoculum was tested by simultaneously culturing a sample
of inoculum on Sabouraud agar.
2.5. Experimental local lung infection, early resection and
histological stain
All rats received inoculum under direct vision through a
small thoracotomy into the peripheral tissue of right upper
lobe 5 days after beginning of immunosuppression. In resec-
tion groups lobectomy was performed on day 13 after
inoculation. The thoracotomy was reopened, the lobe
clipped at the base (Premium Surgiclip M 11.5 Auto Suture,
Tyco Healthcare Ltd., Wollerau, Switzerland) and removed
aseptically. A smear of the lobe was taken on Sabouraud and
the complete lobe sent for histological examination. Hema-
toxylin–eosin, PAS and Grocott-stains were performed. In
non-resected animals the complete right lung was removed
at autopsy together with the other organs as described
below.
2.6. Immunosuppression, supportive care and experimental
setting
Persistent neutropenia was induced according to the
method described by Leenders et al. [11] and Van Etten et
al. [12]. Cyclophosphamide 90 mg/kg per day was injected
i.p. 5 days before fungal inoculation, followed by repeated
doses of cyclophosphamide 60 mg/kg per day at 4-day inter-
vals on days 21, 13, 17, 111, etc. By obtaining blood
samples through orbital puncture under light anesthesia on
a regular basis this immunosuppressive regime has been
demonstrated to lead to profound neutropenia beginning 5
days after first dose of cyclophosphamide [11]. In the
present study leukocyte counts were determined from
blood samples at the time of death or sacrifice to confirm
aplasia (automatic blood cell counter: Advia 120, Bayer
Diagnostics, Mu¨nchen, Germany).
Animals were kept under strict hygienic conditions and
allowed free rodent laboratory fodder (Kliba Mu¨hlen Ltd.,
Kaiseraugst, Switzerland) and water. To prevent bacterial
superinfection amoxicillin i.m. (40 mg/kg per dose) was
added daily beginning on day 21 and gentamycin i.m. (6
mg/kg per dose) was given on days 21 and 0. In amphoter-
icin B (Am B) treatment groups Am B i.p. (1 mg/kg per day)
was begun 48 h after inoculation. Mycelial growth is known
to be firmly established after 30 h in neutropenic rats [12].
Animals were checked daily and mortality was recorded up
to 28 days after which surviving rats were killed (in rats
surviving for longer time periods the influence on survival
by other factors such as anemia and bacterial infections
become a major concern). From all animals both lungs,
liver, spleen and kidneys were removed, and examined
macroscopically and histologically. At the time of death
or sacrifice residual fungal disease was classified as either
absent, local disease or disseminated disease. Ipsilateral
histologically verified fungal manifestations in the inocu-
lated lung, pleura or thoracic wall were defined as local
disease. Disseminated disease was defined as histologically
verified invasive aspergillosis in one or more of the follow-
ing organs: contralateral lung, mediastinum, liver, spleen,
kidneys and retroperitoneal space.
2.7. Statistical analysis
To compare categorical variables among groups the chi-
squared or the Fisher’s exact test were used where appro-
priate. Survival of rats was analyzed using the Kaplan–
Meier estimator and compared among groups using the
log-rank test. Rats surviving to 28 days and killed at that
time were considered censored observations.
3. Results
Median white blood cell count was 0:53 £ 109=l and
median neutrophil count 0:11 £ 109=l.
Survival probabilities at 28 days were 30 ^ 21% (95%
confidence interval) in the group not receiving Am B, and
60 ^ 22% in the group receiving Am B (P ¼ 0:0085).
Survival was 40 ^ 22% in animals not undergoing early
resection, and 50 ^ 22% (P ¼ 0:412) in animals with
early resection.
J.M. Habicht et al. / European Journal of Cardio-thoracic Surgery 22 (2002) 728–732 729
Early resection did not lead to improved survival in
animals treated with Am B, (survival 70 ^ 29% without
early resection and 50 ^ 32% with early resection;
P ¼ 0:316), but significantly higher survival was observed
in resected animals in the non-Am B group (survival:
10 ^ 19% without early resection and 50 ^ 32% with
early resection; P ¼ 0:044) (Fig. 1).
IPA was observed in all resected lobes histologically.
When dissemination occurred (43%), the liver was most
often involved (77%), followed by spleen (35%), contralat-
eral lung (18%), mediastinum (6%) and retroperitoneum
(6%). No IPA manifestations in kidneys and brain were
observed in this series. At death or autopsy local disease
was seen in 25% of animals undergoing early resection
and in 65% of animals without early resection
(P ¼ 0:011). Dissemination of disease was observed in
50% of animals undergoing early resection and in 35% of
animals without early resection (P ¼ 0:337) In the subgroup
of animals not receiving Am B, dissemination of disease
was observed in 50% of animals undergoing early resection
and in 60% of animals without early resection (P ¼ 0:653).
In the same subgroup local disease was seen in 30% of
animals undergoing early resection and in 90% of animals
without early resection (P ¼ 0:021). Absence of disease at
death or sacrifice was observed in 50% of animals treated
with Am B and 20% of animals not treated (P ¼ 0:047).
4. Discussion
The incidence of IPA is reported to vary from 2 to 14% in
hematologic patients in the literature [10,13–16]. Inhalation
of conidia by immunocompetent individuals rarely has any
adverse effect, since conidia are eliminated efficiently by
immune mechanisms [17]. Conidia enter the lungs through
the airways and in neutropenic patients the mycelium then
infiltrates through the bronchial wall into adjacent pulmon-
ary arteries causing thrombosis and infarction [18], which
facilitates further mycelial growth and hampers induction of
effective antifungal drug concentrations. Seemingly,
outcome of IPA is more dependent on marrow regeneration
and termination of immunosuppressive state than on any
therapeutic strategy, but antifungal drugs such as amphoter-
icin B or azole derivatives are the standard of care. Although
general contamination of the bronchial tree with conidia
must be assumed, a diffuse fungal pneumonia is rarely
seen in humans at the time of diagnosis. Initially the disease
is typically localized, offering the possibility of early adju-
vant resection.
Animal models for IPA have been established in a variety
of species and there is no consensus about the best model.
The models most often employed are those used in rabbits
[19–21], rats [11,12,22] and mice [23–25] and were devel-
oped to study the efficacy of antifungal drugs or to evaluate
diagnostic methods. Challenge protocols vary considerably
in terms of concentration of conidia as well as route of
injection (intranasal, intratracheal or intravenous). Of
note, all comparable published models use intratracheal or
intrabronchial inoculation with aspergillus conidia, thus
leading to widespread lung involvement. We chose an
established rat model of neutropenia and diffuse IPA
[11,12] and with a direct injection into peripheral lung
parenchyma aimed at simulating the clinical situation with
a localized focus. Thoracotomy and injection under direct
vision was chosen in contrast to blind intercostal injection in
order to avoid intrapleural contamination and intravascular
spread into major pulmonary vessels. Although great care
was given to avoid any undesirable propagation of conidia
by the above mentioned mechanisms, there is no tool avail-
able to exclude this possibility. However, no case of diffuse
unilateral intrapleural aspergillosis nor any animal dying
exceptionally early of diffuse multiple organ spread was
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Fig. 1. Effects of resection of a focus of localized invasive pulmonary aspergillosis (IPA) in animals with and without amphotericin B treatment (1 mg/kg per
day). Neutropenic rats were inoculated in right upper lobe with 2 £ 104 Aspergillus fumigatus conidia at time zero (Kaplan–Meier plot).
observed, supporting the probability that no intravascular
dissemination occurred during injection.
Our results show resection of localized IPA to improve
survival in animals not treated by Am B. Early resection is
effective through local control of IPA rather than through
prevention of disseminated disease. Dissemination was
found in 50–60% in resected and non-resected animals.
This supports the hypothesis that resection will not cure
fungal disease in most instances but might be useful to
gain time for hematological reconstitution of IPA-patients
so treated. The slightly higher incidence of disease dissemi-
nation observed in resected animals could point to a danger
of disseminating aspergillosis through surgery. The differ-
ence of dissemination between resected animals and
animals not undergoing resection was, however, not signif-
icant and this would have to be studied in a larger experi-
mental series and preferentially also in the human setting.
Resection may be undertaken more extensively in humans
as opposed to small experimental animals which may mini-
mize the danger of iatrogenic dissemination, but in our
formerly published clinical comparative series [10] there
was no evidence of a larger rate of disseminated disease
in patients undergoing surgery as opposed to patients treated
conservatively. It is probable that surviving non-Am B
animals showing distant organ involvement would have
eventually died of IPA later on if they had not been killed
at end of observation period. However, resection enabled
more animals to reach cut-off point at 28 days. In the clinical
situation the time gained may in part explain the good
results reported in surgical series in patients with reversible
aplasia. The fact that at autopsy a substantial number of non-
resected animals treated with Am B showed absence of any
fungal manifestation, together with the observation that IPA
could be demonstrated in all early resection specimens,
supports the interpretation that Am B-treated neutropenic
animals may spontaneously clear an IPA-manifestation
even when caused by a major dose of conidia, as long as
it originates and stays confined to a single small focus. In
animals not treated with Am B such an observation could
not be made, inasmuch as none of the non-resected animals
were disease-free, even if surviving up to 28 days.
Results shown here may not be transferred easily to IPA
encountered in neutropenic patients. In contrast to the clin-
ical situation, this experiment precisely defines onset of
neutropenia and onset of fungal infection. Therefore the
restriction of the beneficial effect of early resection to
animals not treated with Am B and the limitation of its effect
to local control may not be valid in the human situation.
Experimentally induced aspergillosis is a hyperacute infec-
tion obtained with a high concentration of conidia given at a
single point in time. In humans IPA is often a more indolent
disease caused by continuous or repeated exposure to small
numbers of conidia, and time of initiation of antifungal
treatment varies considerably.
The value of early resection in the human situation is not
clear. So far only observational studies are available
suggesting a beneficial effect. Localized invasive aspergil-
losis is often operated on even though there is little evidence
for these interventions. The current experimental study
shows that resection can be life-saving in animals not
receiving early antifungal treatment. In the clinical situation
where antifungal treatment is often initiated only at a time
when invasive aspergillosis is well established, resection
strategies could prove equally beneficial. It is only through
a large randomized study comparing resection strategies to
more conservative treatment that such a benefit could be
proven.
We conclude that in the presented rat model of localized
invasive pulmonary aspergillosis early resection of a single
fungal lesion improved survival in a subgroup of animals.
Early resection was effective for local control of the
disease but did not necessarily prevent systemic spread.
A beneficial effect of resection could be observed if
animals were not simultaneously treated with amphotericin
B.
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